To establish a prospective, multicenter, biopsie-confirmed clinical cohort of MAFLD-related cirrhosis (F3-F4) in China, and analyze the clinical, histopathological features and natural outcomes of MAFLD-associated liver fibrosis/cirrhosis in China. And than to conducted a real-world study of different strategies of Chinese characteristics for the prevention and treatment of MAFLD-related cirrhosis to evaluate the efficacy and safety of the strategies.
Study Type
INTERVENTIONAL
Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
1,000
Drug intervention for 24 weeks and follow-up for another 72 weeks (fasting blood glucose was controlled below 7.0mmol/l throughout the study)
Chinese patent medicine or hypoglycemic drugs other than pioglitazone metformin tablets, pioglitazone, metformin, GLP1
Drug-free
Controlled attenuation parameter (CAP)
Time frame: Through study completion, an average of 96 week.
Transient elastography
Time frame: Through study completion, an average of 96 week.
Model for end-stage liver disease score
Model for end-stage liver disease score ranges from 6 to 40 score (\>40 calculated as 40 scores)，higher scores mean a worse outcome
Time frame: Through study completion, an average of 96 week.
Portalvein pressure gradient(HVPG)
Time frame: Through study completion, an average of 96 week.
Prevalence of cirrhosis
Time frame: Through study completion, an average of 96 week.
Prevalence of liver transplantation
Time frame: Through study completion, an average of 96 week.
Prevalence of decompensated cirrhosis
Time frame: Through study completion, an average of 96 week.
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.